DUBLIN--(BUSINESS WIRE)--The "US Market Report for Dental Growth Factor 2017 - MedCore" report has been added to Research and Markets' offering.
Dental growth factor products currently offered to the U.S. market in 2016 were GEM 21S®, INFUSE®, Osteocel® and Emdogain. Over the forecast period, a number of additional growth factor combinations are expected to enter the tissue engineering product market. In 2005, the FDA approved the release of BioMimetic's GEM 21S®, the first growth factor matrix approved for dental use. The product has since gained traction and received the CE mark approval to enter the European market in 2012.
In late 2006, Medtronic's INFUSE®, a growth factor containing bone graft product, was also approved for dental use. Tissue engineering products are often employed in combination with bone graft substitutes. Certain products cater to a specific need; for that reason, the various growth factors in the market are not viewed as complete substitutes or directly in competition with one another.
Key Topics Covered:
1. Research Methodology
2. Disease Overview
3. Product Assessment
4. Dental Growth Factor Market
Companies Mentioned
- AB Dental
- ACE Surgical
- BTI
- Benco
- Bicon
- BioHorizons
- Collagen Matrix
- Cortex Dental
- Curasan
- Datum Dental
- Dentium USA
- Dentsply Sirona
- Dyna Dental
- Geistlich
- Henry Schein
- Impladent LTD
- Implant Direct
- Inion
- KaVo Kerr
- Keystone Dental
- LifeNet Health
- MIS Implants
- MegaGen
- Nobel Biocare
- NovaBone
- Osteogenics
- Osteohealth
- Patterson
- Regenetix
- Salvin
- Snoasis Medical
- Straumann
- Tissue Banks
- Unicare Biomedical
- Zimmer Biomet
For more information about this report visit https://www.researchandmarkets.com/research/4fmqq8/us_market_report
